CoChat

Early growth, pubertal development, body mass index and final height of patients with congenital adrenal hyperplasia: factors influencing the outcome

Manoli, I., Kanaka‐Gantenbein, Ch., Voutetakis, A., Maniati‐Christidi, M., Dacou‐Voutetakis, C. · 2002 · Clinical Endocrinology
Cited by 100

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Summary: objective The management of children with congenital adrenal hyperplasia (CAH) remains a challenge, especially with regard to growth potentials. The objective of our analysis was to uncover the factors that influence the growth and final height of patients with CAH. design The linear growth pattern and body mass index (BMI) at different developmental stages (birth to 2 years, 2 years to puberty initiation and puberty initiation to final height) and the final height achieved were analysed retrospectively in 48 patients with 21‐hydroxylase deficiency; 17 with the salt‐wasting (SW) form, 25 with the simple virilizing (SV) and six with the nonclassical (NC) form. results Mean final height (FH) and FH‐SDS were, respectively, 170·8 ± 5·6 m and −0·57 ± 0·8 in males and 156·7 ± 6 cm and −0·61 ± 1 in females with the SW form, 166·1 ± 6·1 cm and −1·05 ± 1 in males and 151·6 ± 5·4 cm and −1·4 ± 1 in females with the SV form and 159·7 ± 6·9 cm and 0·3 ± 1·4 in females with the NC form. In subjects with the SW form, height SDS at 2 years, at puberty initiation and at FH were −0·18 ± 0·9, 0·11 ± 1·28 and −0·6 ± 1·0, respectively. FH achieved was not different from target height (TH) in the SW group, but it was significantly lower than TH in the SV group (P = 0·003). FH in the SW group showed a positive correlation to the height achieved at 2 years of age (r = 0·68, P = 0·019), and height at 2 years was negatively related to the hydrocortisone dose in the birth to 2‐year period (r = −0·79, P = 0·011). FH showed no correlation to hydrocortisone dose at any of the three developmental periods studied. BMI‐SDS were not different in the various forms of CAH and showed no correlation to FH or hydrocortisone dose. Age at menarche was comparable to that in our general population. conclusions Under our conditions of management, the final height of patients with the salt‐wasting form was comparable to the target height and to the most favourable literature data. The patients with the simple virilizing form fare less well, mainly due to delayed diagnosis and consequent advancement of bone age and early puberty. In salt‐wasting patients, height at 2 years is comparable to normals, it is influenced by the hydrocortisone dose and is related to the final height. Some height is lost during puberty. Hence, monitoring treatment over the first 2 years and during puberty is critical for the outcome in these patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1365-2265.2002.01645.x

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 100

Metadata

Authors
Manoli, I., Kanaka‐Gantenbein, C., Voutetakis, A., Maniati‐Christidi, M., & Dacou‐Voutetakis, C.
Venue
Clinical Endocrinology
Publisher
Wiley
Published
2002-10-22
Volume
57
Issue
5
Pages
669-676
ISSN
  • 0300-0664 (ISSN-L)
  • 1365-2265
OpenAlex
W2099933339
Cited by
100
References
8
FWCI
1.08
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Early growth, pubertal development, body mass index and final height of patients with congenital adrenal hyperplasia: factors influencing the outcome. https://app.cochat.ai/papers/10.1046/j.1365-2265.2002.01645.x
The paper
Manoli, I., Kanaka‐Gantenbein, C., Voutetakis, A., Maniati‐Christidi, M., & Dacou‐Voutetakis, C. (2002). Early growth, pubertal development, body mass index and final height of patients with congenital adrenal hyperplasia: factors influencing the outcome. Clinical Endocrinology. https://doi.org/10.1046/j.1365-2265.2002.01645.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.